Phosphorylase alpha activity in rat uterine homogenates. Loss of activity related to in vivo treatment with estrogen, progesterone, relaxin and CaEDTA.
D000818:Animals; D002118:Calcium / Q000494:pharmacology*; D002369:Castration; D004336:Drug Antagonism; D004492:Edetic Acid / Q000494:pharmacology*; D004958:Estradiol / Q000494:pharmacology*; D004965:Estrogen Antagonists; D005260:Female; D005964:Glucosyltransferases / Q000378:metabolism*; D006003:Glycogen / Q000096:biosynthesis; D006600:Hexosephosphates / Q000378:metabolism; D007700:Kinetics; D010053:Ovary / Q000502:physiology; D010710:Phosphates / Q000378:metabolism; D011374:Progesterone / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D012065:Relaxin / Q000494:pharmacology*; D013997:Time Factors; D014599:Uterus / Q000187:drug effects / Q000201:enzymology*
D004965:Estrogen Antagonists; D006600:Hexosephosphates; D010710:Phosphates; D011374:Progesterone; D004958:Estradiol; D012065:Relaxin; D006003:Glycogen; D004492:Edetic Acid; D005964:Glucosyltransferases; D002118:Calcium